Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ImmuPharma logo — company profile

ImmuPharma

Founded 1999 11-50 employees Post-IPO Equity Total: $8.70M Biotechnology, Developer Tools +2

General Information

Company Name ImmuPharma
Founded Year 1999
Founders / Decision Makers
Team member
Employees 11-50
Industries Biotechnology, Developer Tools, Life Sciences +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with ImmuPharma. To contact ImmuPharma, visit immupharma.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ImmuPharma compare?

A PDF of ImmuPharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ImmuPharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ImmuPharma

ImmuPharma is a biotech company that focuses on developing innovative drugs for specialized therapeutic areas with limited or no existing treatments, distancing itself from primary care where numerous solutions already exist, a smart move reflecting current trends in the pharmaceutical industry. Since its establishment in 1999, ImmuPharma has strategically prioritized collaboration with the Centre National de la Recherche Scientifique (CNRS) in France, Europe's largest fundamental research organization. This partnership provides access to advanced research at a relatively low cost and enables close work with leading scientists and doctors. ImmuPharma holds exclusive rights to all its intellectual property assets. In February 10, 2016, the company received a significant £8.30M post-IPO equity investment from Lanstead Capital. The company operates in the Biotechnology, Developer Tools, Life Sciences, and Pharmaceutical industries.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £8.30M 1
Lanstead Capital
Lanstead Capital
10 Feb 2016
Post IPO Equity €400.00K -
20 Oct 2014

FAQ About ImmuPharma

ImmuPharma dedicates itself to developing innovative and unique drugs in specialized therapeutic areas that currently have limited or no treatments, steering clear of primary care where numerous solutions already exist. This aligns with prevailing trends in the pharmaceutical industry. Since our inc...
ImmuPharma was founded in 1999.
ImmuPharma operates in Biotechnology, Developer Tools, Life Sciences and Pharmaceutical.
ImmuPharma has approximately 11-50 employees.
ImmuPharma has completed 2 funding rounds, raising a total of $8.70M. The latest funding stage is Post-IPO Equity.

We're actively collecting intelligence on ImmuPharma.

Source: BounceWatch company record for ImmuPharma, https://bouncewatch.com/company/immupharma, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes